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บทคดัยอ่  
วตัถปุระสงค:์ เพือ่ประมาณประสทิธภิาพของยากลุม่ทีม่ใิช่บสิฟอสโฟเนต ในการ
ป้องกนักระดูกสนัหลงัหกัจากโรคกระดูกพรุนในหญงิวยัหมดประจ าเดอืนโดยการ
ทบทวนวรรณกรรมอย่างเป็นระบบและวเิคราะห์อภมิาน วิธีการศึกษา: สบืคน้
งานวจิยัจากฐานข้อมูลอิเล็กทรอนิกส์ ได้แก่ MEDLINE และ Cochrane Library 
ตัง้แต่เริม่มฐีานขอ้มูล จนถงึเดอืนพฤศจกิายน 2558 คดัเลอืกงานวจิยัเชงิทดลอง
แบบสุม่ทีม่กีลุม่ควบคุมทีเ่ปรยีบเทยีบประสทิธผิลของยากลุม่ทีม่ใิช่บสิฟอสโฟเนต
ได้แก่  denosumab, raloxifene, strontium ranelate, teriparatide และ tibolone 
กับการให้ยาหลอกหรือ/และแคลเซียมร่วมกับวิตามินดี โดยวัดผลลัพธ์เป็น
อุบตักิารณ์การหกัของกระดูกสนัหลงั วเิคราะห์อภมิานประสทิธผิลของยาโดย
แสดงดว้ยค่าอตัราเสีย่งสมัพทัธ์ (risk ratio) และช่วงความเชื่อมัน่ 95% (95% CI) 
ผลการศึกษา: จากการสบืคน้พบงานวจิยัทีผ่า่นการคดัเลอืกตามเกณฑท์ีก่ าหนด
ไว ้12 เรื่อง งานวจิยัศกึษาเปรยีบเทยีบกบัผลของยากลุม่ทีม่ใิช่บสิฟอสโฟเนตกบั
การใหย้าหลอก มรีะยะเวลาการศกึษาอยูใ่นช่วง 1 ปี ถงึ 3 ปี ผลการวเิคราะหอ์ภิ
มานพบว่าการใหย้า denosumab, strontium ranelate และ teriparatide สามารถ
ป้องกนัการเกดิกระดกูสนัหลงัหกัไดม้ากกวา่กลุม่ควบคุมอยา่งมนียัส าคญัทางสถติ ิ 
ดว้ยค่า RR = 0.33 (95% CI: 0.26 - 0.41), 0.60 (95%CI: 0.53-0.69) และ 0.26 
(95%CI: 0.14-0.49) ตามล าดบั ผลของการใหย้า raloxifene ในการป้องกนัการ
เกดิกระดกูสนัหลงัหกันัน้ไมแ่ตกต่างจากกลุม่ควบคุม (RR = 0.76; 95% CI: 0.41 
- 1.40) สว่นยา tibolone มเีพยีง 1 การศกึษาจงึวเิคราะหอ์ภมิานไมไ่ด ้สรปุ: ยาใน
กลุ่ ม ที่ มิ ใ ช่ บิสฟอส โฟ เ นต  ไ ด้ แ ก่  denosumab, strontium ranelate และ 
teriparatide มปีระสทิธภิาพในการป้องกนักระดกูสนัหลงัหกัจากโรคกระดกูพรุนใน
หญงิวยัหมดประจ าเดอืน อย่างไรก็ตาม หลกัฐานเชงิประจกัษ์ของยา raloxifene 
และ tibolone ยงัมีจ ากดั ดงันัน้การน าข้อมูลของยาสองตวันี้ไปใช้ในการรกัษา
ผู้ป่วยหญิงวยัหมดประจ าเดอืนที่เป็นโรคกระดูกพรุนจงึควรระมดัระวงัและควร
ศกึษาเพิม่  
ค าส าคญั: กระดูกหกั, หญงิวยัหมดประจ าเดอืน, โรคกระดูกพรุน, ยากลุ่มทีม่ใิช่
บสิฟอสโฟเนต, การทบทวนวรรณกรรม, การวเิคราะหอ์ภมิาน  
 
 
 
Abstract 
Objective: To determine efficacy of non-bisphosphonate drugs for preventing 
osteoporotic vertebral fracture in postmenopausal women by systematic 
review and meta- analysis.  Methods:  Published reports were searched 
through the electronic databases including MEDLINE and the Cochran 
Library ( CENTRAL)  from inception to November 2015.  Randomized 
controlled trial ( RCT)  studies on efficacy of non- bisphosphonate drugs 
including denosumab, raloxifene, strontium ranelate, teriparatide and tibolone 
compared with placebo and/ or calcium plus vitamin D with the outcome of 
incidence of vertebral fracture were selected. Results of pooled efficacy from 
meta-analysis were presented as risk ratio (RR) with 95% confident interval 
(CI) .  Results:  The search identified 12 articles consistent with inclusion 
criteria. The studies compared effects of non-bisphosphonates with placebo 
for 1 -  3 years. It was found that denosumab, strontium ranelate and 
teriparatide significantly prevented vertebral fracture with RR =  0. 33 ( 95% 
CI: 0.26 - 0.41), 0.60 (95% CI: 0.53 - 0.69) and 0.26 (95% CI: 0.14 - 0.49), 
respectively.  Raloxifene was not better than placebo in preventing vertebral 
fracture (RR =0.76; 95% CI: 0.41 - 1.40). Since only one RCT of tibolone, 
its pooled result could not be estimated.  Conclusion: Non-bisphosphonate 
drugs including denosumab, strontium ranelate and teriparatide were 
efficacious in preventing osteoporotic vertebral fracture in post-menopausal 
women.  However, evidences indicating efficacy of raloxifene and tibolone 
were limited; the use of these drugs should be cautious. Further studies are 
needed.   
Keywords:  bone fracture, postmenopausal women, osteoporosis, non-
bisphosphonate, systematic review, meta-analysis  
 
 
   
Introduction 
Post- menopausal women are at a high risk of 
osteoporosis. As a result of a decrease in estrogen hormone, 
the loss of bone mineral density is accelerated.  The 
prevalence of osteoporosis has been 7%  to 35%  and 
increasing with age. 1  In osteoporosis, the bone health is 
detrimental both bone mineral density and the bone one 
quality.  Though symptomatic in early stages, but if left 
untreated, bone fractures at different body parts could be 
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common. A vertebral fracture could put a huge burden on the 
patients, family member and caregivers.  A low level of daily 
living and quality of life for all parties is inevitable. 
Complications such as pressure ulcer and infections are 
common and could lead to death. 2  Since the treatment is 
relatively costly and almost life- long3, measures to prevent 
bone fractures are paramount for osteoporosis.  
Pharmacological treatment has been an effective modality 
for osteoroposis.4,5 According the clinical practice guideline of 
the Royal College of Orthopaedic Surgeons of Thailand and 
Thai Osteoporosis Foundation, bisphosphonates are 
considered the first-line drug for postmenopausal women with 
osteoporosis.6 However, bisphosphonates are associated with 
certain adverse effects on gastrointestinal tract and some 
serious adverse effects such as atypical femoral fractures and 
osteonecrosis of the jaw.  As a result, there are limitations to 
use bisphosphonates in certain groups of patients with a long-
term use.  These adverse effects could lead not only to 
complications and discomforts, but also patient’ s non-
compliance. 5,7- 9 To avoid these adverse events and 
consequences, non- bisphosphonates such as denosumab, 
raloxifene, strontium ranelate, teriparatide and tibolone could 
reasonable alternative to bisphosphonates.  
At present, studies have shown that efficacy of non-
bisphosphonates are inconclusive or contradicting. 10- 13 In 
addition, meta-analysis of randomized controlled trials (RCTs) 
to summarize efficacy of non- bisphosphonates has been 
limited. 14,15 Therefore, there was a need to conduct a meta-
analysis of RCTs of non-bisphosphonates to determine their 
efficacy for osteoporosis in postmenopausal women.  The 
finding could be a useful evidence for selecting non-
bisphosphonates suitable for specific patients.  This study 
aimed to determine efficacy of non-bisphosphonates including 
denosumab, raloxifene, strontium ranelate, teriparatide and 
tibolone in preventing osteoporosis in postmenopausal 
women.  
     
Methods 
 
This study employed a systematic literature review and 
meta- analysis approach.  Only randomized controlled trials 
( RCTs)  examining efficacy of denosumab, raloxifene, 
strontium ranelate, teriparatide and tibolone were included in 
this analysis.  These RCTS needed to compare a given non-
bisphosphonate either with placebo and/ or calcium plus 
vitamin D in postmenopausal women with osteoporosis.  
 
Database and data searching    
Studies were searched from electronic databases such as 
MEDLINE and the Cochrane Library from inception up to 
November 2015 with Medical Subject Heading (MeSH)  and 
keywords of “ Osteoporosis”  [ MeSH] , “ Osteoporosis, 
Postmenopausal”  [ MeSH] , “ Fractures, Bone”  [ MeSH] , 
“ Denosumab” , “ Reloxifene” , “ Strontium ranelate” , 
“Teriparatide” , and “Tibolone,”  with conjunction operators of 
“and”  and “or. ”  Additional RCT studies cited in systematic 
review papers and clinical research papers were also further 
searched.  
 
Selection of RCT studies  
Two investigators (SS, WA)  independently selected RCT 
studies based on inclusion criteria.  If any disagreement or 
discrepancy, opinion from the third investigator (WB)  was 
obtained.  To be eligible, the study needed to be an RCT 
examining efficacy of denosumab, raloxifene, strontium 
ranelate, teriparatide or tibolone compared with lacebo and/or 
calcium plus vitamin D in postmenopausal women with 
osteoporosis.  Outcomes of the study needed to be incidence 
of vertebral fractures. The study had to be published in English 
language. Studies about cost-effectiveness or with information 
inadequate for meta-analysis were excluded.   
 
Data extraction and RCT study quality evaluation  
Selected RCT studies were independently evaluated for 
quality by two investigators (SS, WA). In case of discrepancy 
if any, the third investigator ( WB)  was asked for final 
judgement. Quality evaluation on the RCT studies was guided 
by Maastricht- Amsterdam scale. 16 The scale has a high 
internal validity in evaluating trial bias in 11 aspects including 
( 1)  adequate randomization, ( 2)  concealed treatment 
allocation, ( 3)  comparable baseline characteristics, ( 4) 
interventions blinded to patients, (5)  interventions blinded to 
care providers, ( 6)  interventions blinded to outcome 
assessors, ( 7)  co- interventions avoided or similar, ( 8) 
compliance acceptable in all groups, ( 9)  drop- out rate 
described and acceptable, ( 10)  similar time of outcome 
assessment in all groups, and (11) intention-to-treat analysis 
included.  The answer of each of these 11 aspects of bias is 
in yes-no and unsure format where 1 point is awarded for no 
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risk of bias.  An RCT with a total score of 6 points or higher 
was considered a high quality trial; while those with scores 
lower than 6 points are low quality ones and have a high risk 
of bias.  For data extraction on individual selected RCTs, 
authors, year of publication, study setting, interventions, study 
duration, and age and number of participants.  
 
Data synthesis and summary 
For a given drug namely denosumab, raloxifene, strontium 
ranelate and teriparatide, there needed to be at least two 
RCTs for meta-analysis.  In the analysis, pooled result of the 
risk ratio of incidence of vertebral fractures was estimated. 
The overall effects were presented as risk ratio (RR) with 95% 
confidence interval ( 95%  CI)  in the form of Forest’ s plot. 
Heterogeneity among RCTs was tested based on the work of 
Higgins and colleagues including Q statistics with a 
significance level () of 0.10 and percentage of inconsistency 
index (I2). In pooled result analysis, I2 of ≤ 25% indicated no 
heterogeneity and fixed effect model was chosen; while I2 of 
> 25% indicated significant heterogeneity and random effect 
model was chosen. 17 Analysis was performed using Review 
Manager® (Revman version 5. 3. 5) .  We included 11 RCTs, 
both high and low quality studies, in this analysis.. 
 
Results  
 
 
 
Figure 1  Flow diagram of literature search and study 
selection.  *  Only one study on tibolone, therefore there was no 
need to perform meta-analysis on the drug.   
From a total of 902 articles, after duplicate papers were 
excluded, 12 articles of 12 studies met the inclusion criteria 
(Figure 1).  Most studies had high quality (11 of 12 articles) 
with a score of 6 points or higher; while only one was with low 
quality. Most studies were on denosumab (4 studies), followed 
by raloxifene ( 3 studies) , strontium ranelate ( 2 studies) , 
teriparatide (2 studies) and tibolone (1 study). 
There were 12 studies examining efficacy of non-
bisphosphonate drugs in preventing vertebral fractures. 
However, since only one study of tibolone was found, there 
was no need to perform meta-analysis on the drug.  As a 
consequence, 11 studies were included in meta-analysis.  
Of all 11 RCT studies included for meta-analysis, they 
were published in 1998 to 2014.  Participants were 
postmenopausal women with osteoporosis aged 45 to 95 
years old with and without bone fracture.  Most studies were 
placebo controlled 91.67 (11 studies) while 1 study (8.33%) 
was active controlled with calcium plus vitamin D. 18 Most 
studies were conducted in North America, followed by Latin 
America, Europe and Asia, respectively, and had study 
durations of 1 to 3 years (Table 1). 
The outcomes in these studies were incidences of bone 
fractures including vertebral fractures, non-vertebral fractures, 
hip fractures, and wrist fractures.  Five non-bisphosphonate 
drugs were found in these 11 studies including denosumab, 
raloxifene, strontium ranelate, teriparatide and tibolone.  Of 
these 12 studies examining vertebral fracture prevention, the 
majority tested the efficacy of denosumab ( 4 studies) , 
raloxifene ( 3 studies) , strontium ranelate ( 2 studies) , 
teriparatide (2 studies), and tibolone (1 study). Efficacy of non-
bisphosphonates in preventing non- vertebral fractures was 
found in a small number of studies.  Specifically, only one 
study reported hip fracture prevention. 1 9 - 2 3  Wrist fracture 
prevention was tested with raloxifene20, strontium ranelate21 
and teriparatide22, each with one study.  
In the meta-analysis, 11 studies with incidence of vertebral 
fractures were included.  Non-bisphosphonate drugs included 
for meta-analysis were denosunab (4 studies) , raloxifene (3 
studies) , strontium ranelate (2 studies)  and teriparatide (2 
studies) .  There was no need to perform meta-analysis on 
tibolone since only one study with incidence of vertebral 
fractures was found.  
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 Table 1  Characteristics of selected RCT studies.   
Drug Study 
Year of 
publication 
Study setting 
Study populations 
Tested intervention 
Study  
duration 
Study 
quality* Age (yr) 
Number  
(test / 
control) 
Denosumab         
 1. McClung 2006 24 2006 America ≥ 80  47 / 46 Denosumab 60 mg q 6 mo. 12 mo. High  
 2. Bone 2008 25 2008 America, Canada Average: 59  166 / 166 Denosumab 60 mg sc q 6 mo. 24 mo. High 
 3. Cummings 2009 
(FREEDOM trial) 19 
2009 Europe, Latin America, 
North America, Australia, 
Australia, New Zealand 
60 – 90 3,906 / 3,902 Denosumab 60 mg sc q 6 mo. 36 mo. High 
 4. Nakamura 2014: DIRECT 
trial26 
2014 Japan ≥ 50 500 / 511 Denosumab 60 mg sc q 6mo. 24 mo. Low 
Raloxifene         
 5. Lufkin 199818 1998 America 45 - 75  48,47 / 48 Raloxifene 60 mg/d, 120 mg/d 12 mo. High 
 6. Ettinger 1999: MORE 
Trial20 
1999 N/A Average: 65  5,129 / 2,576 Raloxifene 60 mg/d, 120 mg/d 36 mo. High 
 7. Morii 2003 27 2008 Japan ≥ 80 92,92 / 95 Raloxifene 60 mg/d, 120 mg/d 52 wk. High 
Strontium ranelate        
 8. Meunier 2004: SOTI trial28   2004 Europe, Australia ≥ 50 828 / 821 Strontium ranelate 2 g/d 36 mo. High 
 9. Reginster 2005: TROPOS 
trial21 
2005 Europe, Australia 70 – 74 2,554 / 2,537 Strontium ranelate 2 g/d 36 mo. High 
Teriparatide         
 10. Neer 2001:  Fracture 
Prevention Trial (FPT)22 
2001 N/A Average: 69 541,552 / 544 Teriparatide 20 µg sc OD, 40 
µg sc OD.   
24 mo. High 
 11. Nakamura 2012-b:  
TOWER trial 29 
2012 Japan 65 – 95 290 / 288 Teriparatide sc 56.5 µg/wk.   72 wk. High 
Tibolone         
 12. Cummings 2008: LIFT 
study23 
2008 N/A 60 - 85 2,267 / 2,267 Tibolone 12.5 mg/d  34 mo. High 
   * Study quality based on Maastricht-Amsterdam scale (high quality: ≤ 6 points; low quality: < 6 points).    
  
Effects of non-bisphosphonate drugs in preventing vertebral factures 
Denosumab  
In 4 studies of denosumab19,24-26, the dose was 60 mg sc 
every 6 months for 1 to 3 years. With a total of 9,026 patients, 
denosumab 60 mg sc every 6 months offered a significant 
67% protection of vertebral fracture compared with placebo 
(RR = 0.33; 95%CI: 0.26 - 0.41). Among these 4 studies, no 
heterogeneity was found (I2 = 2%, P-value = 0.38) (Figure 2).  
 
Raloxifene  
In 3 studies of raloxifene18,20,27,  the dose was 60 to 120 
mg/ day for 1 to 3 years.  With a total of 7,241 patients, 
raloxifene 60 -  120 mg/ day resulted in a 24% protection of 
vertebral fracture compared with controls with no statistical 
significance (RR = 0.76; 95%CI: 0.41 - 1.40). This could be 
in part due to a significant heterogeneity among studies ( I2 
=78%, P-value = 0.01) (Figure 3).  
 
Strontium ranelate  
In 2 studies of strontium ranelate21,28,  the dose was 2 
g/ day for 3 years.  With a total of 5,082 patients, strontium 
ranelate 2 g/ day offered a significant 40%  protection of 
vertebral fracture compared with controls (RR = 0.60; 95%CI: 
0. 53  -  0.69) .  Between the 2 studies, no heterogeneity was 
found (I2 = 0%, P-value = 0.85) (Figure 4).  
 
Teriparatide  
In 2 studies of teriparatide22,29,  the dose was v for 2 years. 
With a total of 1,888 patients, teriparatide 20 – 40 µg/day and 
56. 5 µg/ week resulted in a significant 74%  protection of 
vertebral fracture compared with controls (RR = 0.26; 95%CI: 
0.14 - 0.49). Between the 2 studies, a moderate heterogeneity 
was found (I2 = 53%, P-value = 0.14) (Figure 5).  
 
Tibolone  
The was only one study on tibolone with a dpose of 1.25 
mg/ day for 2 years and 10 months. 23 With a total of 4,506 
patients, tibolone 1. 25 mg/ day offered a significant 44% 
protection of vertebral fracture compared with controls (RR = 
0.56; 95%CI: 0.42 - 0.74). 
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 Figure 2  Efficacy of denosumab in reducing the risk of vertebral fracture compared with controls.  
 
 
  
 Figure 3  Efficacy of raloxifene in reducing the risk of vertebral fracture compared with controls. 
 
 
  
 Figure 4  Efficacy of strontium ranelate in reducing the risk of vertebral fracture compared with controls. 
 
 
 
 Figure 5  Efficacy of teriparatide in reducing the risk of vertebral fracture compared with controls. 
 
 
Discussions and Conclusion  
 
In this meta-analysis, more RCTs studies were included 
compared with previous meta-analysis studies.  As a result, 
our present study was supposedly to offer a more robust 
finding of efficacy of non-bisphosphonate drug for preventing 
vertebral fractures in postmenopausal women.  Findings from 
our study were consistent with the previous ones.  
In this present study, denosumab was found to be 
significantly efficacious in preventing vertebral fractures in 
postmenopausal women with osteoporosis.  This finding was 
consistent with previous studies of Keyserlingk and 
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colleagues10 and Silva- Fernandez and co-workers30 where 
similar sample size and osteoporotic postmenopausal women 
were found.  However, our finding was different from that of 
Anastasilakis et al where a smaller sample size of mixed pre- 
and post- menopausal women with osteoporosis were 
recruited in the study.11  
For raloxifene, a slight protection on vertebral fracture was 
found with no statistical significance. As we had learned from 
the work of Cranney and colleagues13, two RCTs of Ettinger 
et al20 and Lufkin et al18 with dramatically different sample 
sizes were tried for pooling ( 6,828 and 133 patients, 
respectively) , but not successful.  Therefore, in our study, we 
included another study by Mori and colleagues27, yet 
raloxifene was found not different from control.  We found that 
study of Mori and colleagues27 had a small sample size and 
the outcomes of fracture also included decrease in bone 
length.  However, the heterogeneity among these studies 
caused the insignificant finding in our analysis.  
We also found that strontium ranelate was significantly 
protective of vertebral fractures.  This finding was consistent 
with systematic review of O’ Donnell and colleagues31 and 
meta- analysis of Kanis et al. 32 For teriparatide, it was 
significantly efficacious in preventing vertebral fractures.  The 
finding was consistent with Han and co-workers probably in 
part due to similar sample size and characteristics.33 However, 
we found that heterogeneity between the two studies included 
in our analysis was in moderate level probably because of 
differences in dosage frequencies namely once a day and 
once a week, as well as the given doses (20 – 40 µg/day and 
56.5 µg/week).  
For tibolone, there was only one study in postmenopausal 
women with osteoporosis. This one study was also terminated 
before completion. 23 There has been no study on tibolone 
since 2008.  All studies on tibolone has been small and had 
no outcomes of incidence of bone fractures.  
Our study found that RCT studies on raloxifene and 
teriparatide had significant heterogeneity probably in part due 
to differences in sample size, outcomes, and dosage 
regimens.  Our study also faced certain limitations since 
publication bias and sensitivity were not tested.  
There were certain advantages in our study.  First, 
systematic searching of studies was conducted.  Second, a 
wide range of non-bisphosphonates was studied.  Third, the 
outcome of bone fracture especially vertebral ones was a 
highly objective outcome which is also the major target of the 
fracture prophylaxis treatment in women with osteoporosis. 
Fourth, we included mostly high quality RCT studies in our 
analysis which could offer a robust and practical result. 
However, certain limitations were presented in our study. 
It was possible that some articles might be missed since 
databases available for us were relatively slightly limited and 
only studies with English language were included.  It was 
recommended that future research with an access to a wider 
range of databases should be conducted to get a more precise 
and reliable effect estimation. Moreover, with a relatively small 
number of RCT studies, publication bias and sensitivity 
analysis were not performed in our study.  Hence, the robust 
conclusion could not be drawn with full confidence. In addition, 
with diverse mechanisms of action of these non-
bisphosphonates and their dosage regimens, a 
comprehensive single estimate on efficacy of these non-
bisphosphonates could not be made.  The interpretation and 
practical use of our findings could thus be limited.  Another 
limitation was that non-bisphosphonates are not the first- line 
drugs for osteoporosis, hence the use was conditional. Some 
RCT studies included patients with osteopenia but subgroup 
analysis was not provided.  This shortcoming could cause 
heterogeneity among RCT studies and estimates of efficacy 
from these studies could be inconclusive.  
In conclusion, non- bisphosphonate drugs including 
denosumab, strontium ranelate and teriparatide were 
efficacious in preventing vertebral fractures in 
postmenopausal women with osteoporosis. However, efficacy 
of raloxifene and tibolone was found inconclusive with limited 
evidence.  The use of raloxifene and tibolone in preventing 
vertebral fractures in postmenopausal women with 
osteoporosis should be cautioned and more studies are 
needed.  
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